PROSPECTIVE REAL WORLD EVIDENCE: USE OF BRENTUXIMAB VEDOTIN AS CONSOLIDATION THERAPY AFTER AUTOLOGOUS TRANSPLANT IN HODGKIN LYMPHOMA. AN INTERIM ANALYSIS, ON BEHALF OF GATLA.

Autor: Fiad, L., Altuve, J., Cerutti, A., Salvano, L., Guanchiale, L., Aranguren, F. Negri, Warley, F., Kurgansky, N., Castro, M., Bentolila, G., Stemberg, E., Cruset, S., Korin, L., Mariano, R., Pereyra, P., Mahuad, C., Pavlovsky, A.
Předmět:
Zdroj: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p676-676, 1p
Abstrakt: B Conclusions: b This is the only prospective evidence describing the acceptance and indication of consolidation therapy with BV in a patient with RR HL. We analyzed patients' characteristics, previous lines of treatment, response before and after transplant. Of the 53 evaluable patients, 57% only received 1 salvage therapies, 24% 2 and 19% received 3 or more salvage therapies before Auto-SCT. [Extracted from the article]
Databáze: Complementary Index